hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:40:33 - browse：34599

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

hotspot

WSS

Juul spent big to court Black leaders to promote its e

Ancient Greek ideas underpin modern concepts of pregnancy

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

State of the Union pitch: Bigger Medicare drug price negotiations

Juul spent big to court Black leaders to promote its e

Cognito secures funding to test medical device for Alzheimer's

entertainment

hotspot

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

United colonoscopy coverage change 'may cost lives,' doctors say

A $475,000 price tag for a new cancer drug: crazy or meh?

What does generative AI mean for health care? We asked experts

Juul spent big to court Black leaders to promote its e

Trump demands the U.S. pay no more for drugs than other countries … again

The public health thinking behind the CDC’s new Covid guidance

Supreme Court strikes down use of affirmative action

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

entertainment

Immune cells and nerve overgrowth may explain recurring UTI pain

Cybersecurity threat forces Lurie Children's to take systems offline

For AI in health care standards, federal regulators join with industry group

Biden's 'march

Time to name cancers by genetics, not organ of origin, expert says

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

hotspot

hotspot

hotspot

focus